Your Global Leader in Stem Cell Market Research
High-quality Human iPSC-based discovery services for CNS and pain research.
| January 26, 2017 – Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]
Akron Biotech is part of the Advanced Regenerative Manufacturing Institute (ARMI) consortium to develop next-generation manufacturing processes and technologies for cells, tissues and organs. The ARMI will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs.
Melbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval. [Read more…]
Quincy, MA (metropolitan Boston) LeukoLab facility serves as company’s second US-based hematologic tissue collection site, increasing assurance of supply and accelerating delivery of fresh and frozen products to eastern region and global life science researchers. [Read more…]
Regeneus Ltd (ASX: RGS), a clinical stage regenerative medicine company, today announced it has received US$5.5m from AGC as an upfront payment for the exclusive rights to manufacture Progenza under the terms of the collaboration and licence announced on 29 December 2016.
Regeneus is expected to receive a further US$11m in specific development and approval milestone payments.
Regeneus will be entitled, through its 50 per cent interest in Regeneus Japan, to its share of upfront licence fees, milestone payments and royalties from sub licensing the development and commercialisation of Progenza for osteoarthritis and all other clinical indications in Japan. [Read more…]
